Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow DTIL
Precision BioSciences, Inc. (DTIL) EV/Sales
As of 16 October 2026, Precision BioSciences, Inc. (DTIL) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −4.2× (March 2023) to 114× (October 2025); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.2× | — |
| FY2024 | −0.6× | — |
| FY2023 | −1.5× | — |
| FY2022 | −2.6× | — |
| FY2021 | 2.5× | (82.54%) |
| FY2020 | 14.5× | (19.70%) |
| FY2019 | 18.1× | 14.56% |
| FY2018 | 15.8× | 0.00% |
| FY2017 | 15.8× | 0.00% |
| FY2016 | 15.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.3× | — |
| Dec 2025 | −1.2× | — |
| Sep 2025 | 61.2× | 1,086.93% |
| Jun 2025 | 5.2× | — |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.9× |
| DTIL Precision BioSciences, Inc. | 1.9× |
| CHRS Coherus Oncology, Inc. compare | 5.1× |
| ORMP Oramed Pharmaceuticals Inc. compare | 29.0× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)